Member Info for Multibagger13

Some early guesses as to what year end June 2017 post tax / net income could be...we could be in the region of £750-800k (without any further contracts being announced.) Market cap of around £5.8m, PE of around 7.6 and net income of around £750-800k and the likelihood of a dividend - what's not to like ? Any thoughts ? Good luck all :)

Given that our expenses are already more than covered for by existing revenue, I would surmise that these additional revenues are pure profit. So since Aug 2016...annual, recurrent revenue highlighting RNS include 18.08.2016 = £285k 23.09.2016 = £ 95k 02.12.2016 = £115k Total additional revenue pa = £495k The market will very soon realise how undervalued we are....wake up folks :)

Fourfold as I see it, albeit a layman's perspective 1. Possible short term supply pressures in salmon availability and resultant price hike 2. Restocking implications - may benefit BMK 3. The fact that fish lice is a real issue that needs urgent addressing - BMK vaccine in pipeline 4. This is not the first time that large quantities of salmon stock have been lost to thermal treatment.

Thanks for the info Miss Womble - that could well explain the share price rise and agree that there could be more to come in the short term... hxxps://theferret.scot/fish-farm-firm-kills-175000-salmon-accident Good luck all :)

Marketing - I did ask a question on these lines. It wasn't that they don't want to recruit marketing staff - I got the sense that they have tried before and for whatever reason it became more of an overhead rather than translated to revenue. They also mentioned that sometimes we are used as a bargaining chip by customers against the Reuters and Bloomberg to get a better deal from them. So the issue of employing people and given the time and training required to get them upto speed, has to be balanced with the revenue that they bring in. Apart from this, given the highly technical nature of our products, any customer requests re software modification pulls in the senior software architect so that in turn affects development work. At the moment, we appear to be focussing on getting more value per customer (through selling a wider range of products) rather than increasing our client footprint. Also banks wish to have a consistent point of contact and therefore it makes sense that our existing marketing team focus more on our current client base. However, given movement of staff between banks, some have actually been able to drum up interest in ARC interest from their new employers - which is a testament to the quality of our products. This may translate to new business in the fullness of time given the very long sales cycles which more often than not involves displacement of the incumbent vendor. So though it seems counterintuitive given our cash pile, the marketing issues have clearly been looked at very closely and an appropriate decision taken.

I attended the AGM and there were three other private investors and therefore a low key event. From the information shares, it appears that the company is making steady progress and it appears that we may hit double digit percent organic growth in the near future. There was a comment that “we have not scratched the surface” of the markets we serve indicating there were opportunities to cross sell and upsell to existing customers. When asked about increasing the sales force, we were told that getting the people with the right mix of marketing, technical and relationship skills for this very niche area product was time consuming and any recruitee would have to have some significant training before being able to make an impact. So on balance a conservative approach is being taken and it appears to be working. Our ability to customise software and adapt software architecture in a matter of weeks/months as opposed to years was appreciated by customers not accustomed to this level of service from the big boys of Reuters and Bloomberg. Our desktop product suite is attracting decent interest (as mentioned in one of the recent RNS). With the presence of NOMADs, there was no possibility of any forward looking statements, but I got the sense that an expectation of a progressive dividend policy would not be misplaced. This is my reading of the situation and I could be wrong. I asked about Brexit and was told that was not expected to affect our relationships with our customers or where they choose to base. With regards to the cash pile, I got the sense that given the long history and the uphill task and perseverance it has taken to get here, that the management was very conservative about its use. A right acquisition was not ruled out if the opportunity arose. Equally, any prospective predator would have to pay a good premium before major holders would be interested – given we may be heading to the sweet spot of solid growth in the coming years with the extremely sticky recurrent income. We were told that over the last 10 years, only 2-3 customers had terminated. Staff turnover was also reassuring low with a number of employees having taken equity stake in the company. I really enjoyed the atmosphere of the company, ethos and culture albeit this being surmised from a short visit. My warm congratulations to Matthew Jeffs and the team and I had the pleasure of also interacting with Louise Barton, Richard Last, Michael Levy, Darren Lewis and Sarah Wisbey and they all came across as very decent, dependable, astute, well engaged and focussed individuals who will certainly build good share holder value with time. With consolidation now out of the way, I hope we have a continuation of the renewed energy, vigour and newsflow that we have seen over the last several months. Let's hope that consolidation is beneficial for our shareprice - I am optimistic it will be, though stock market history of consolidations indicates a pull back m

Excellent news ...twice in a couple of months with numbers attached. I like the newsflow. Slowly but surely...we are growing in solid way and remember most of the new contract annoucement revenue will go straight to the bottom line. So these last 2 announcements (18 Aug and today) alone mean an additional £380k pa...which is almost double the current profits.Onwards and upwards ! Congratulations to Matthew and the team who are doing a great job :)

You are most welcome...and nice to see a new share price high today. More good news to come in the fullness of time and dividend payment is likely to draw wider market attention. Fincapp has a new 0.5p target and we are already at 0.45p. Good luck all :)

I'm not sure that its their PR people coming up with "companion animal", but I have heard vets use such language in terms of their area of specialisation. Horse owners (as race horse, stud farm, farm and companion animal owners) are generally are well off - I'm sure that they won't skimp on what is good for Barney or whoever :) I took another 15992 earlier this afternoon....any price at close to the most recent placing price is great IMHO. BMK is way undervalued and has very good medium to long term growth prospects.

Hi thechukkers....share price has appreciated about 100% over last 12 months and has touched 5 year high. No debt, £1.6m cash, dividend imminent post share consolidation, new products now in trials with several Tier 1 banks, very sticky customers....directors and Anthony Cross hold about 40% between them. It's a boring stock but often the best shares are like that....I'm delighted to hold a good few :)

Another strong and commercially valuable addition to the IP portfolio :) I like the way they are slotting different companies in to build and grow a well rounded portfolio with options for cross selling and upselling. The current share price is also attractive and I took another 11k shares the other day. I am also pleased that Ferd has built a decent stake - contrary to what some one else has posted, to me it is a greater vote of confidence to buy in your own backyard (on the presumption that you are more likely to know what is going on there) than in some remote part of the world, where you may not have the local intelligence. The integrations of the various acquisitions is going to take time but we should be very different looking company in about 3 years time....if we have not been bought out by then ! Good luck all :)

My conservative guess as to what the full year to 30 June 2016 will be... purely finger in the air and nothing scientific about it ! Revenue: £ 2.27 - 2.28m Operating profit: £ 320 - 340k Cash balance: £ 2.2 to 2.35m Possible announcement of a small maiden dividend with abundant dividend cover. ...would invite those with an accounting background to hazard a guess as to the possible figures. TIA Hopefully another interesting and upward movement day today :)

Interview from 15 July 2016 hxxp://www.proactiveinvestors.co.uk/companies/stocktube/5292/brexit-won-t-derail-learning-technologies-50mln-ambition-ceo-5292.html

Been a long time since I checked the company website - it has been refreshed and appears that we have an expanded suite of software. The tagline has been refreshed to "creating advantage" For the first time, the company has advertised some of our customers Bank of England Barclays Citi Lloyds Santander JP Morgan Morgan Stanley Nykredit We are coming upto our results announcement (was announced on 05 Aug last year) will reflect strong progress with atleast 10% growth in revenues and the prospect of the long awaited dividend ! Good luck all :)

Another superb set of figures....well done Idea :) RNS Number : 5290E 19 July 2016 Ideagen PLC ("Ideagen" "the Company" or "the Group") Unaudited Preliminary Results for the Year Ended 30 April 2016 Ideagen PLC (AIM: IDEA), a leading supplier of Information Management software to highly regulated industries, announces its unaudited preliminary results for the year ended 30 April 2016. Financial Highlights · Revenue increased 52% to £21.9 million (FY2015: £14.4 million) o Underlying organic growth of 10% (FY2015: 5.3%) o Recurring revenues of £11.5 million at year end (FY2015: £10.6 million), covering 88% of operating costs (FY2015: 84%) · Adjusted diluted EPS** increased 26% to 2.66 pence (FY2015: 2.11 pence) · Adjusted EBITDA* increased 57% to £6.3 million (FY2015: £4.0 million) · Adjusted PBT** increased 58% to £5.7 million (FY2015: £3.6 million) · Cash generated by operations of £4.9 million (FY2015: £2.2 million) · Net cash of £6.3 million (FY2015: £5.3 million) · Proposed final dividend of 0.122 pence per share o Making a total dividend of 0.183 pence per share for the year (FY2015: 0.165 pence per share) in line with our policy of growing annual dividends by a minimum of 10% Operational Highlights · Strong growth in SaaS business driven by investment in Enlighten, Ideagen's cloud based Governance, Risk and Compliance (GRC) platform o Landmark contract awarded for Enlighten with the Railway Safety and Standards Board worth £4.9 million over 5 years o Additional 15 SaaS deals, including Providence Financial, WAMOS Air, HNZ Global and Air Greenland · Over 100 new on-premise customer wins including Schiphol Airport, DHL, Cobalt Air, Meggitt and South West Yorkshire NHS Trust · Significant contract extensions and expanded engagements within existing customer base, including PWC, Haeco, Babcock, Bristow Helicopters, BTG and Dartford and Gravesham NHS Trust · Continued high levels of customer retention with support and maintenance contract renewal rate of 96% (FY2015: 96%) · Ongoing product innovation and investment across all products *Before share based payments and exceptional items **Before share based payments, amortisation of acquisition intangibles and exceptional items David Hornsby, CEO of Ideagen, commented: "Ideagen has enjoyed another year of strong growth. Having expanded the business considerably with seven acquisitions completed in the previous four years, adding significant product capabilities and expertise to the Group, the year's focus was on driving forward our enlarged operations and executing the organic growth strategy. "The market for GRC management solutions remains fragmented and the drivers are long term and highly strategic. Trading since the ye

Great RNS - strong IP and Euro 300m market potentially and more is vaccine is developed for other farmed fish species RNS Number : 5178E Benchmark Holdings PLC 19 July 2016 Benchmark's new seabass vaccine commences commercial field trials Benchmark is pleased to announce that one of its new generation aquaculture vaccines has been released into the market for commercial field trials. The vaccine is the first in a series of Benchmark's new vaccines targeted at the €300m Mediterranean seabass market and aims to provide producers with an effective control of Nodavirus - a disease that impedes growth and causes high production losses. There was previously no effective treatment available for this endemic disease. The trials will see a significant number of leading producers use the new vaccine 'on-farm' at commercial scale ahead of market authorisation, a process which typically takes 9 to 12 months. Full development of the product has been undertaken in-house through exploiting the Group's R&D expertise, vaccine manufacturing capability and aquaculture trials facilities to ensure a streamlined and secure development process. Nodavirus also affects several other farmed aquaculture species including Turbot, Barramundi and Grouper, and Benchmark now plans to provide these sectors with a similar solution. The development process for producing this vaccine for seabass can now be readily adapted to bring forward vaccines for these other species. Malcolm Pye, Benchmark's CEO commented: "This is another key milestone for Benchmark and is testament to our increased capability, as we continue to invest in our manufacturing capacity and technology, to open up new markets for the company by solving major challenges for our customers. This product represents a significant first for the Company, as the full development process including research, design, development and manufacturing, has been delivered entirely in-house by our specialist teams."

I did see the ED presentation - quite a long one. The most interesting part for me was the pipeline and stages at which various products were in development. I particularly like the business model and the way that the divisions interlink synergestically. The Directors have decent skin in the game and I think that the move into tilapia and shrimp will generate a lot of revenue from the developing economies. Apart from all this, the current market price offers a good margin of safety compared to placing price. I have taken a little over 154k shares so far and intend to hold for a minimum of 3-5 years for starters. This time frame is likely to be transformational and I would not rule out the possibility of a takeover by a food giant at a good premium to where we are now. Good luck all :)

33% increase in salmon prices over the 12 weeks....good for us :) hxxps://salmonprice.nasdaqomxtrader.com/public/report;jsessionid=C3FC13A62EF50EFEAA9995A70E6D42FB?0 Added another 18k this morning - though at a premium today still at a significant discount to the 85-86p placement not too long ago. Good luck all :)

With SIM revenues being US dollar based, the weakening pound should be beneficial for us - purely from that perspective. However, overall we are shafted with more expensive imports.

Strong results despite Chile issue. A lot of their products are dollar benchmarked as are some debt - so forex impact on financials has been pointed out. Overall I'm very pleased as these results are only demonstrate the very start of the transformation of the company.